Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
08.07. | Eupraxia Pharmaceuticals Inc: Eupraxia doses first patient in phase 2b Resolve trial | 1 | Stockwatch | ||
08.07. | Stocks in Play: Eupraxia Pharmaceuticals Inc. | - | Baystreet.ca | ||
08.07. | Eupraxia Pharmaceuticals Inc.: Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis | 48 | GlobeNewswire (Europe) | Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required... ► Artikel lesen | |
EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
08.07. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.06. | Canaccord Genuity initiates Eupraxia stock with spec. buy on EoE treatment | 2 | Investing.com | ||
03.06. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders | 82 | GlobeNewswire (Europe) | VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
07.05. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 | 1 | GlobeNewswire (USA) | ||
07.05. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results | 132 | GlobeNewswire (Europe) | Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to... ► Artikel lesen | |
05.05. | Eupraxia Pharmaceuticals Inc: Eupraxia talks treatment outcomes in phase 1b/2a trial | 2 | Stockwatch | ||
05.05. | Stocks in Play: Eupraxia Pharmaceuticals Inc. | - | Baystreet.ca | ||
05.05. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
24.04. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
21.03. | Eupraxia Pharmaceuticals reports Q4 results | 3 | Seeking Alpha | ||
20.03. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results | 157 | PR Newswire | VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology... ► Artikel lesen | |
26.02. | Eupraxia Pharmaceuticals is undervalued, Research Capital says | 2 | Cantech Letter | ||
25.02. | Eupraxia Pharmaceuticals Inc: Eupraxia talks EP-104GI Resolve study clinical data | 2 | Stockwatch | ||
25.02. | Eupraxia reports progress in EoE drug trial with promising results | 1 | Investing.com | ||
25.02. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis | 134 | PR Newswire | Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase
Cohort 6 showed the greatest symptom relief... ► Artikel lesen | |
25.02. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 42,730 | +2,82 % | QIAGEN N.V.: QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels | Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications... ► Artikel lesen | |
ABIVAX | 58,00 | +563,62 % | Abivax explodiert über 400%: Was bedeuten diese Daten? | Die französische Biotechfirma Abivax liefert starke Phase-3-Daten ihres Medikamentenkandidaten Obefazimod. Die Nasdaq-notierte Aktie schnellt über 400% durch die Decke. Was ist jetzt noch drin? Abivax... ► Artikel lesen | |
EVOTEC | 6,358 | +2,05 % | Evotec-Aktie mit Kursgewinnen (7,326 €) | Am deutschen Aktienmarkt liegt die Aktie von Evotec aktuell im Plus. Der jüngste Kurs betrug 7,33 Euro. Für das Wertpapier von Evotec steht gegenwärtig ein Wertanstieg 0,33 Prozent zu Buche. Die Aktie... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 28,010 | +5,58 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
ARCELLX | 69,97 | +2,51 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 57,09 | +3,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 55,74 | +4,03 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,430 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
BIONTECH | 96,90 | +3,36 % | Novo Nordisk, BioNxt Solutions, BioNTech - so heilen Sie Ihr Portfolio mit der Gesundheits-Revolution 2025 | Das globale Gesundheitswesen erlebt 2025 eine Zeitenwende. Klimafolgen, chronische Krankheiten und Pandemienarben fordern Systeme heraus, während Digitalisierung und KI rasant neue Therapien vorantreiben.... ► Artikel lesen | |
KYMERA THERAPEUTICS | 46,430 | 0,00 % | Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? | ||
ARCUTIS BIOTHERAPEUTICS | 14,910 | +2,47 % | Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth | ||
DYNE THERAPEUTICS | 9,380 | +1,74 % | Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More | ||
ARS PHARMACEUTICALS | 18,000 | 0,00 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
VERVE THERAPEUTICS | 11,110 | +0,27 % | Aktien New York Schluss: Verluste - Sorgen um Krieg in Nahost nehmen zu | NEW YORK (dpa-AFX) - Die sich zuspitzende Lage in Nahost und die Unsicherheit über das weitere Vorgehen der USA haben am Dienstag die US-Börsen belastet. Der New Yorker Leitindex Dow Jones Industrial... ► Artikel lesen | |
NURIX THERAPEUTICS | 11,630 | 0,00 % | Nurix Therapeutics: Günstiger BTK-Player | In der Welt der Biotechnologie zählt die gezielte Zerstörung krankheitsverursachender Proteine zu den innovativsten Ansätzen der modernen Arzneimittelforschung. Nurix Therapeutics, ein Unternehmen mit... ► Artikel lesen |